Actinium Pharmaceuticals Initiates First Clinical Trial for Actimab-A Triplet Combination in AML
Actinium Pharmaceuticals, a trailblazer in the field of targeted radiotherapies, has announced the initiation of a new clinical trial under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). This trial, identified by the number NCT06802523, will explore the use of a triplet combination in the treatment of acute myeloid leukemia (AML) patients.
The Triplet Combination
The triplet combination consists of Actimab-A, an alpha-emitting radiotherapeutic, Venetoclax, an oral Bcl-2 inhibitor, and ASTX-727, a novel oral hypomethylating agent (HMA). Actimab-A targets CD45, a protein expressed on the surface of both cancer cells and healthy cells, making it a mutation-agnostic therapy. By selectively delivering radiation to the leukemia cells, Actimab-A spares healthy cells and reduces side effects.
Previous Clinical Data
Previously, Actimab-A has demonstrated synergistic potential in combination with other therapies. Two Phase 1 trials have been completed: one with Venetoclax (Actimab-A + Venetoclax) and another with CLAG-M (Actimab-A + CLAG-M). These trials showed promising results, indicating that the combination therapies could increase the efficacy of Actimab-A and potentially improve patient outcomes.
Expansion into Frontline Setting
The initiation of this new clinical trial marks a significant expansion of the potential addressable patient opportunity for Actimab-A. By exploring the triplet combination in the frontline setting, Actinium aims to further understand the therapeutic potential of Actimab-A and improve treatment options for AML patients.
Impact on Individuals and the World
For individuals diagnosed with AML, this new clinical trial represents a potential advancement in the treatment landscape. Actimab-A’s mutation-agnostic and synergistic properties could lead to more effective and personalized treatments, ultimately improving patient outcomes and quality of life.
On a global scale, the success of this clinical trial could pave the way for the widespread adoption of targeted radiotherapies in the treatment of AML and potentially other hematological malignancies. By selectively delivering radiation to cancer cells, targeted radiotherapies could minimize side effects and enhance the efficacy of existing treatments.
Conclusion
Actinium Pharmaceuticals’ announcement of the initiation of the first clinical trial for the Actimab-A triplet combination in AML marks an exciting step forward in the field of targeted radiotherapies. With initial clinical data expected in the second half of 2025, this research has the potential to significantly impact the lives of AML patients and broaden the scope of treatment options. Stay tuned for further updates on this groundbreaking development.
- Actinium Pharmaceuticals initiates clinical trial for Actimab-A triplet combination in AML
- The triplet combination consists of Actimab-A, Venetoclax, and ASTX-727
- Previous Phase 1 trials demonstrated synergistic potential
- Expansion into frontline setting could improve patient outcomes
- Potential impact on individuals and the world
